BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients
Public ClinicalTrials.gov record NCT02276781. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The investigators hypothesize that among people with lower extremity peripheral artery disease (PAD), biomarker levels are higher during time periods immediately preceding an acute coronary event compared to time periods not immediately preceding an acute coronary event. Biomarkers the investigators will study are CRP, SAA, and D-dimer. Biomarkers will be measured at baseline and every two months during follow-up. The primary aims of this study are as follows. Specific Aim #1. Among participants with PAD who experience an acute coronary event during follow-up, the investigators will determine whether biomarker levels measured immediately prior to the coronary event are higher than levels that do not immediately precede coronary events. Specific Aim #2, Part 1. The investigators will determine whether participants who experience a coronary event (cases) have higher biomarker levels at the visit immediately prior to the event than participants who have not experienced a coronary event (controls) at the time of the case event. Specific Aim #2, Part 2. The investigators will determine whether participants who experience a coronary event (cases) have a greater increase in biomarkers during the time period leading up to the event compared to participants who have not experienced a coronary event (controls). To achieve these aims, the investigators will enroll up to 650 participants with PAD and follow them prospectively, measuring blood samples every two months, and ascertaining the presence of acute coronary events every two months.
Study identification
- NCT ID
- NCT02276781
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 595 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2009
- Primary completion
- Dec 31, 2012
- Completion
- Dec 31, 2012
- Last update posted
- May 5, 2015
2009 – 2013
United States locations
- U.S. sites
- 6
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mt. Sinai Medical Center | Chicago | Illinois | 60608 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Jesse Brown Veterans Administration Medical Center | Chicago | Illinois | 60612 | — |
| Rush Medical Center | Chicago | Illinois | 60612 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| St. Joseph's Hospital | Chicago | Illinois | 60657 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Peripheral Arterial Disease trials
Other public records listing Peripheral Arterial Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT00424866: FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease Not yet recruiting
- NCT07619885: The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants Recruiting
- NCT06319339: Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease Recruiting
- NCT07223593: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease Recruiting
- NCT05811364: The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease Recruiting
- NCT07335341: Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02276781, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2015 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02276781 live on ClinicalTrials.gov.